• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

MID Programs Provide Real-Time Patient Monitoring, Explains Dr Christie Smith

Commentary
Video

The real-time monitoring of patients through medically integrated dispensing (MID) programs can reduce costs of care and remove barriers, said Christie Smith, PharmD, MBA, vice president, pharmacy and payer strategy, Cencora.

Medically integrated dispensing (MID) can help reduce cost of care through real-time monitoring of patients to address adverse effects in a timely manner, said Christie Smith, PharmD, MBA, vice president, pharmacy and payer strategy, Cencora.

In her session, Smith discussed innovative care models and MID programs. She was joined by Marci Conlin, vice president, pharmacy network management, Prime Therapeutics/Magellan Rx Management; and Kyle Verley, director, network management, Prime Therapeutics.

Transcript

How are innovative care models, such as MID programs, working to remove barriers to care and address disparities?

We are constantly working to help address SDOH, social determinants of health. Our providers are stretched all over the place, and so we try to support them in helping patients get the right resources to what they need, basic resources. I think that it is challenging. It is challenging. I think we need more nonprofit organizations to help not only physicians but payers. I think the payers need to provide some sort of financial support so that providers and the entire community can afford to help their patients in those ways.

What are innovative care models implementing to reduce costs of care?

So, for example, in the model that we're participating in, what plans have seen is that MID actually is a cheaper cost model than specialty pharmacy. I've worked for a specialty pharmacy in my lifetime. I love specialty pharmacy. But there are certain situations where it would make sense for certain therapies to be considered in this model. Basically, the total cost of care has been reduced under the [MID] model. And I think I sort of alluded to some examples like you can see in real time if a patient will or will not need the medication due to disease progression, side effect management from the cost of that drug.

That side effect management is so critical because this where, if a patient is having severe diarrhea, because that’s a common reaction, and they have to go to the hospital to get treated because of dehydration and all of that, that cost avoidance is huge for a medical plan vs when this script is outside of the practice’s direct authority.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Michael Morse, MD, Duke Cancer Center
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.